SHANGHAI – Beigene Co. Ltd. is betting its Bruton's tyrosine kinase inhibitor, BGB-3111, has world-class potential and is gearing up for proof-of-concept trials in the U.S. to find out. The company just received approval for its investigational new drug application from the FDA and is beginning to build up its U.S.-based operation to support the upcoming trials.